# Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT07003737** · NA · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 114 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, B-precursor

## Interventions

- **DRUG:** Blinatumomab
- **OTHER:** Consolidation Chemotherapy or Direct Allogeneic HSCT

## Key facts

- **NCT ID:** NCT07003737
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-05
- **Primary completion:** 2027-02-05
- **Final completion:** 2028-02-05
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003737, "Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07003737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*